Scribe Therapeutics Inc. (SCTX)
NASDAQ: SCTXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
SCTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $228.58M
- EPS (TTM)
- -$6.35
- Dividend yield
- None
- 52-week range
- 12.00 – 39.60
- Day range
- 12.00 – 13.40
- Volume / Avg
- 301.40K / 403.27K
- Beta
- —
- Shares outstanding
- 18.94M
- Next earnings
- Dec 2, 2026
52-week range
SCTX stock today
Scribe Therapeutics (SCTX) closed at $12.07 on Nov 20, down 8.70% (-$1.15), versus the S&P 500's 3.70% decline. At this level, SCTX sits near the bottom of its 52-week range of $12.00 to $39.60: 69.5% below the high, set on Aug 20, 2026 and 0.6% above the low. Scribe Therapeutics has posted a net loss over the last twelve months (EPS of -$6.35), so its P/E ratio is not meaningful.
The company is scheduled to report Sep/2026 results on Dec 2; analysts expect EPS of -$0.42.
Summary generated from market data by MetaCap's automated system. Methodology
About Scribe Therapeutics
Company profileScribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Benjamin L. Oakes Ph.D.
- Headquarters
- Alameda, CA
- Employees
- 77
- IPO year
- 2026
- Website
- scribetx.com
Analyst forecast
ForecastConsensus (4 analysts)
strong_buy
Avg. price target
$57.00+372.25%
- Strong buy 0
- Buy 4
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Dec 2, 2026
- EPS estimate
- $-0.42
- Last reported (Sep/2026)
- Dec 2, 2026
- EPS actual vs est.
- $-0.68 vs $-0.42
- Surprise
- -61.90%
SCTX news
All SCTX news- Scribe Therapeutics Reports Long-Lasting Cholesterol Reduction And Promising Lp(a) DataNasdaqSCTX, HEI.A
- Scribe Therapeutics Presents New Data Advancing the Potential of Ultra-Long-Acting Genetic Medicines for Cardiovascular Disease at AHA Scientific Sessions 2026GlobeNewswire
- Cathie Wood Bought Just 3 Stocks On Monday; Here They AreNasdaqNVDA, SCTX, SOFI
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtNasdaqCRWV, FRNM, SCTX
- Biotech Stocks At 52-Week Highs - SCTX Continues Rise After Nasdaq Debut, RPRX, HAE, TXG, LHNasdaqHAE, LH, RPRX, SCTX
Scribe Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALLOAllogene Therapeutics Inc. | 0.6277 | -5.88% | $217.48M | vs SCTX |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs SCTX |
| PLXProtalix BioTherapeutics Inc. (DE) | 2.90 | -5.23% | $244.52M | vs SCTX |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs SCTX |
| IPSCCentury Therapeutics Inc. | 1.17 | -11.74% | $211.56M | vs SCTX |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs SCTX |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs SCTX |
| CABACabaletta Bio Inc. | 0.9361 | -7.32% | $201.94M | vs SCTX |
Indexes, lists and sector
Scribe Therapeutics stock FAQ
What is Scribe Therapeutics's stock price today?
SCTX last traded at $12.07 as of Nov 20, 4:00 PM EST, down 8.70% on the day. Prices are delayed at least 15 minutes.
When is Scribe Therapeutics's next earnings date?
Scribe Therapeutics is expected to report earnings on Wednesday, December 2, 2026. Analysts expect EPS of $-0.42.
Who is Scribe Therapeutics's CEO?
Dr. Benjamin L. Oakes Ph.D. is the chief executive officer of Scribe Therapeutics Inc., which has about 77 employees.
What is the SCTX 52-week high?
The 52-week high for SCTX is $39.60 and the 52-week low is $12.00. The stock is currently 69.5% below its high.